| Title: | Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas |
| Authors: | Uchinami, Yusuke Browse this author |
| Katoh, Norio Browse this author →KAKEN DB |
| Abo, Daisuke Browse this author |
| Taguchi, Hiroshi Browse this author |
| Yasuda, Koichi Browse this author |
| Nishioka, Kentaro Browse this author |
| Soyama, Takeshi Browse this author |
| Morita, Ryo Browse this author |
| Miyamoto, Naoki Browse this author |
| Suzuki, Ryusuke Browse this author |
| Sho, Takuya Browse this author |
| Nakai, Masato Browse this author |
| Ogawa, Koji Browse this author |
| Kakisaka, Tatsuhiko Browse this author |
| Orimo, Tatsuya Browse this author |
| Kamiyama, Toshiya Browse this author |
| Shimizu, Shinichi Browse this author |
| Aoyama, Hidefumi Browse this author →KAKEN DB |
| Keywords: | albumin-bilirubin grade |
| hepatocellular carcinoma |
| real-time tumor-tracking radiotherapy |
| stereotactic body radiotherapy |
| Issue Date: | 3-Aug-2021 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Hepatology Research |
| Volume: | 51 |
| Issue: | 8 |
| Start Page: | 870 |
| End Page: | 879 |
| Publisher DOI: | 10.1111/hepr.13649 |
| Abstract: | Aim To report the outcomes of stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinoma patients. Methods From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter <= 52 mm were treated by stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. No patient with a Child-Pugh Score >= 9 was included, and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with an alpha/beta ratio of 10 (BED10), the median dose in BED10 at the reference point was 76.8 Gy (range 60-122.5 Gy). Overall survival (OS) and local control rates were assessed using the Kaplan-Meier method. Results With a median follow-up period of 24.6 months (range 0.9-118.4 months), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI] 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1, and 61.7% in patients with grade >= 2a. In the multivariate analysis, the mALBI grade (=1 vs. >= 2a) was a significant factor for OS (p = 0.028, 95% CI 1.11-6.18). The 1-year and 2-year local control rates were 100% (100-100%) and 92.0% (77.5-97.5%). The local control rates were significantly higher in the BED10 >= 100 Gy group than in the BED10 <100 Gy group (2-year 100% vs. 86.5%, p = 0.049) at the reference point. Conclusion This retrospective study of stereotactic body radiotherapy using real-time tumor-tracking radiotherapy for hepatocellular carcinoma showed favorable outcomes with lower incidence of toxicities, especially in patients treated with BED10 >= 100 Gy to the reference point. |
| Rights: | This is the peer reviewed version of the following article: Uchinami, Y, Katoh, N, Abo, D, Taguchi, H, Yasuda, K, Nishioka, K, et al. Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas. Hepatology Research. 2021; 51: 870– 9. which has been published in final form at 10.1111/hepr.13649. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/86500 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
